Literature DB >> 18398017

Protein adsorption during LDL-apheresis: proteomic analysis.

Hassan Dihazi1, Michael J Koziolek, Tanja Söllner, Elke Kahler, Reinhard Klingel, Rieke Neuhoff, Frank Strutz, Gerhard A Mueller.   

Abstract

BACKGROUND: The aim of our study was to investigate the clearance of functional proteins by different low-density lipoprotein-apheresis (LDL-A) methods with the help of proteomic analyses.
METHODS: Proteins were eluated from the different LDL-A columns and investigated with 2D electrophoresis combined with mass spectrometry methods. In parallel, we quantified the plasma protein loss from patients treated with double-filtration plasmapheresis (DFPP; n = 9), direct adsorption of lipoproteins (DALI; n = 5) or heparin-induced extracorporeal LDL precipitation (HELP; n = 7) with routine laboratory methods and western blots.
RESULTS: Proteomic analyses of the column-bound proteins revealed a column-type-dependent loss with the highest number of protein spots in DALI-treated patients (1001 +/- 36), followed by HELP (881 +/- 25) and DFPP (535 +/- 20). More than 70 functional proteins were identified. These proteins are involved in the coagulation pathway (e.g. kininogen1) and have adhesive (e.g. fibronectin), rheological (e.g. fibrinogen) and immunological/inflammatory properties (e.g. complement components). Quantification with western blot analyses demonstrated a significant depletion (P < 0.01) of these proteins comparing serum samples before and after the column with a systemic lowering in patients' serum.
CONCLUSIONS: These data reveal strong interaction between column and serum proteins during LDL-A. The clearance of proteins with adhesive, rheological, and inflammatory characteristics may have beneficial effects on microcirculation and reduce chronic inflammation but may also concomitantly induce side effects such as an increased bleeding risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398017     DOI: 10.1093/ndt/gfn127

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis.

Authors:  Hagai Tavori; Ilaria Giunzioni; MacRae F Linton; Sergio Fazio
Journal:  Circ Res       Date:  2013-10-11       Impact factor: 17.367

Review 2.  Lipoprotein apheresis.

Authors:  Vijay G Bhoj; Bruce S Sachais
Journal:  Curr Atheroscler Rep       Date:  2015-07       Impact factor: 5.113

3.  Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report.

Authors:  Gianpaolo Russi; Luciana Furci; Marco Leonelli; Riccardo Magistroni; Nicola Romano; Paolo Rivasi; Alberto Albertazzi
Journal:  J Med Case Rep       Date:  2009-12-02

4.  Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis.

Authors:  Michael J Koziolek; Desiree Tampe; Matthias Bähr; Hassan Dihazi; Klaus Jung; Dirk Fitzner; Reinhard Klingel; Gerhard A Müller; Bernd Kitze
Journal:  J Neuroinflammation       Date:  2012-04-26       Impact factor: 8.322

5.  Low-density lipoprotein apheresis is associated with removal of SARS-CoV-2 antibodies.

Authors:  Sebastian Bertram; Thiemo Pfab; Christian Albert; Sven Schmidt; Jürgen Passfall; Martin Haesner; Maximilian Seidel; Bodo Hölzer; Felix S Seibert; Adrian Doevelaar; Benjamin Rohn; Panagiota Zgoura; Nina Babel; Timm H Westhoff
Journal:  Ther Apher Dial       Date:  2022-03-29       Impact factor: 2.195

6.  Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia.

Authors:  Viktória E Varga; Hajnalka Lőrincz; Noémi Zsíros; Péter Fülöp; Ildikó Seres; György Paragh; József Balla; Mariann Harangi
Journal:  Lipids Health Dis       Date:  2016-10-18       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.